PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2026Lara D. Veeken2 citations

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis

View Full Paper
LSLuisa SchneiderAPAnn‐Christin PecherLHLuca Hensen

Key Points

  • The study aims to evaluate the safety and efficacy of CD19-targeted CAR T cell therapy in ANCA-associated vasculitis.
  • Administration of CD19-targeted CAR T cells to a patient with relapsed GPA
  • Monitoring for safety and efficacy post-treatment
  • The CAR T cell therapy was deemed safe for the patient
  • Efficacy was observed with improvements in disease symptoms
  • Potential for better long-term outcomes in ANCA-associated vasculitis patients

Abstract

CD19-targeted CAR T cell therapy was safe and efficacious in a patient with relapsed and refractory GPA. CAR T cell therapy has the potential to transform disease management and improve long-term outcomes for affected patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schneider et al. (2026) studied this question.

synapsesocial.com/papers/69ba43884e9516ffd37a4e82https://doi.org/10.1093/rheumatology/keag126
Ask AI
Helpful
Bookmark
Share
View Full Paper